1. Subject enrolled in a study to investigate a treatment for COVID-19

2. Require oxygen use, hospitalization or mechanical ventilation

3. Tachycardia (HR \> 150 bpm) or hypotension (BP \< 90/60 mmHg)

4. Patients who are allergic to the investigational product or similar drugs (or any excipients);

5. Subjects with QTcF \> 450 ms

6. Subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (BP \> 220/120 mmHg), uncontrolled hypothyroidism (TSH \> 10 iU/L), uncontrolled diabetes mellitus (HbA1c \> 12%)

7. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \> 5 times the upper limit of normal.

8. Estimated glomerular filtration rate (eGFR) \< 30 ml/min or requiring dialysis

9. Subject (or legally authorized representative) not willing or unable to provide informed consent

10. Not willing to provide informed consent

EAT-DUTA AndroCoV Trial

What this study is about